JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD

  NCT04189562

  Condition:   Attention Deficit/Hyperactivity Disorder
  Intervention:   Other: SMS Intervention
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Indoor Air Quality and Respiratory Morbidity in School-Aged Children With BPD

  NCT04107701

  Conditions:   Bronchopulmonary Dysplasia;   Chronic Lung Disease of Newborn;   Environmental Exposure
  Intervention:  
  Sponsors:   Boston Children’s Hospital;   National Institute of Environmental Health Sciences (NIEHS)
  Recruiting
• Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders

  NCT03967743

  Conditions:   Genetic Disease;   Genetic Syndrome;   Genetic Predisposition to Disease;   Development, Infant;   Development, Child
  Intervention:  
  Sponsor:   Boston Children’s Hospital
  Recruiting
• The Use of Music for Neonates Post-Cardiac Surgery

  NCT03925584

  Condition:   Heart Defects, Congenital
  Intervention:   Other: Music Therapy
  Sponsor:   Boston Children’s Hospital
  Recruiting
• A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth

  NCT03911414

  Conditions:   Mood Disturbance;   Mood Disorders;   Natural Supplements;   Alternative Treatment
  Interventions:   Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol;   Drug: Open-label Treatment with N-acetylcysteine
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Resiliency Training in Adolescents With NF1 and NF2

  NCT03873610

  Condition:   Neurofibromatoses
  Interventions:   Behavioral: Stress and Symptom Management Program 1;   Behavioral: Stress and Symptom Management Program 2
  Sponsors:   Massachusetts General Hospital;   United States Department of Defense
  Recruiting
• Monitoring Of Scratch Via Accelerometry In Children

  NCT03873220

  Condition:   Atopic Dermatitis
  Interventions:   Device: Wrist Actigraphy Devices;   Device: Sleep Monitor;   Device: Polysomnography;   Device: Videography
  Sponsor:   Boston University
  Recruiting
• Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

  NCT03757585

  Conditions:   Non-verbal Learning Disorder;   Autism Spectrum Disorder;   Autism
  Interventions:   Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol;   Drug: Open-label Treatment with N-acetylcysteine
  Sponsors:   Massachusetts General Hospital;   Demarest Lloyd Jr. Foundation
  Recruiting
• CenteringParenting Clinical Intervention on Kindergarten Readiness in Early Childhood

  NCT03641092

  Conditions:   Parent-Child Relations;   Parenting;   Child Development;   Child Behavior
  Interventions:   Behavioral: CenteringParenting Intervention;   Behavioral: Routine Well Child Care
  Sponsors:   Boston Medical Center;   Centering Healthcare Institute;   Overdeck Family foundation;   Valhalla Charitable Foundation
  Recruiting
• Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention

  NCT03638453

  Condition:   Other Cancer
  Interventions:   Other: PediCARE;   Other: Usual Care
  Sponsors:   Dana-Farber Cancer Institute;   Charles H. Hood Foundation;   National Cancer Institute (NCI)
  Recruiting
• Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation

  NCT03532399

  Condition:   Drug Effect
  Intervention:   Drug: Bivalirudin
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Boston Outcomes of Autism in Toddlers Study

  NCT03517163

  Conditions:   Autism Spectrum Disorder;   Autism
  Intervention:  
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

  NCT03447782

  Condition:   New Daily Persistent Headache (NDPH)
  Intervention:   Drug: Naltrexone HCl (Bulk) Powder
  Sponsor:   Boston Children’s Hospital
  Recruiting
• A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

  NCT03432065

  Conditions:   Autism Spectrum Disorder;   Anxiety
  Intervention:   Drug: Buspirone
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  NCT03431064

  Conditions:   Anesthesia;   Intravenous Fluid;   Blood Pressure
  Interventions:   Other: Lung Recruitment Maneuver;   Other: Fluid Administration
  Sponsors:   Boston Children’s Hospital;   Masimo Corporation
  Recruiting
• Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

  NCT03246243

  Condition:   Hypoxic-Ischemic Encephalopathy
  Interventions:   Device: nfant feeding solution;   Device: Waveguard (TM) EEG cap;   Device: BabyMEG
  Sponsors:   Boston Children’s Hospital;   Beth Israel Deaconess Medical Center;   Winchester Hospital
  Recruiting
• Environmental Assessment of Sleep in Youth

  NCT03224455

  Conditions:   Sleep Disorders in Children;   Environmental Exposure
  Intervention:  
  Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital
  Recruiting
• Innovative Approaches to Assessment of Pain Control and Sedation in the NICU

  NCT03057782

  Condition:   Pain, Postoperative
  Interventions:   Device: Waveguard (TM) EEG cap;   Device: Micro Movement Sensor;   Device: Pico Movement Sensor;   Device: QS Piezostimulator;   Device: tactileTM sensory evaluator
  Sponsor:   Boston Children’s Hospital
  Recruiting
• The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric

  NCT03054831

  Condition:   Liquid Oxycodone
  Intervention:   Drug: liquid oxycodone
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Outcomes of an Intraoperative Bispectral Index Monitor

  NCT03052543

  Condition:   Anesthesia
  Intervention:   Device: BIS™ Complete 2--Channel Monitor
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices

  NCT02918435

  Conditions:   Basic Unmet Material Needs;   Patient Satisfaction;   Receipt of Community Resources;   Provider Referrals
  Intervention:   Behavioral: WE CARE
  Sponsors:   Boston Medical Center;   Pediatric Research in Office Settings;   Continuity Research Network;   Boston University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• The Evaluation of a Noninvasive Respiratory Monitor in Intubated Infants

  NCT02899351

  Condition:   Respiratory Complications
  Intervention:   Device: Respiratory Volume Monitor
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Blood Ropivacaine Concentrations Following Nerve Block in Infants and Toddlers Undergoing Esophageal Atresia Repair

  NCT02860091

  Condition:   Pain, Postoperative
  Intervention:   Drug: Ropivacaine infusion
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD

  NCT02708290

  Conditions:   Autistic Disorder;   Autism;   ASD
  Intervention:   Other: MITA imagination exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
  Sponsor:   ImagiRation, LLC
  Recruiting
• Use of Amplification in Children With Unilateral Hearing Loss

  NCT02269124

  Condition:   Unilateral Hearing Loss
  Intervention:   Device: Hearing aid
  Sponsor:   Massachusetts Eye and Ear Infirmary
  Recruiting
• Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  NCT02044497

  Condition:   Pediatric Surgical Patient
  Intervention:   Drug: oral oxycodone
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Tau/P-Tau and Neurocognitive Outcomes in Children

  NCT03511729

  Conditions:   General Anesthetics Toxicity;   Postoperative Cognitive Dysfunction;   Child Development
  Intervention:  
  Sponsor:   Massachusetts General Hospital
  Recruiting
• An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

  NCT01850355

  Conditions:   Autism Spectrum Disorders;   Anxiety
  Intervention:   Drug: Buspirone
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)

  NCT03015272

  Condition:   Autism
  Interventions:   Behavioral: Auditory-Motor Mapping Training;   Behavioral: Speech-Repetition Therapy
  Sponsors:   Beth Israel Deaconess Medical Center;   Boston University
  Recruiting
• Kisspeptin in the Evaluation of Delayed Puberty

  NCT01438034

  Conditions:   Delayed Puberty;   Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   GnRH Deficiency
  Interventions:   Drug: kisspeptin 112-121;   Drug: GnRH
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder

  NCT00592267

  Condition:   Pediatric Bipolar Disorder
  Intervention:  
  Sponsor:   Massachusetts General Hospital
  Recruiting
• NIRS Monitoring in Premature Infants

  NCT02601339

  Conditions:   Hemorrhage;   Premature Infants;   Newborn;   Hydrocephalus
  Intervention:   Procedure: ETV/CPC
  Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease

  NCT04166526

  Condition:   Sickle Cell Disease
  Interventions:   Device: FDNIRS-DCS;   Device: MRI
  Sponsors:   Boston Children’s Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Optical Tissue Identification for Myocardial Architecture

  NCT04017975

  Conditions:   Ventricular Septal Defect;   Complete Atrioventricular Canal;   Tetralogy of Fallot With Pulmonary Stenosis
  Interventions:   Drug: Fluorescite;   Device: Cellvizio 100 Series System with Confocal Miniprobes
  Sponsors:   Aditya Kaza;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• VE416 for Treatment of Food Allergy

  NCT03936998

  Condition:   Peanut Allergy
  Interventions:   Combination Product: Vancomycin plus VE416 before PNOIT;   Combination Product: Vancomycin plus VE416 with PNOIT;   Combination Product: Placebo plus VE416 with PNOIT;   Combination Product: Placebo plus placebo with PNOIT
  Sponsors:   Massachusetts General Hospital;   Vedanta Biosciences, Inc.
  Recruiting
• Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

  NCT03936465

  Conditions:   Solid Tumor, Childhood;   Lymphoma;   Brain Tumor, Pediatric
  Intervention:   Drug: BMS-986158
  Sponsors:   Dana-Farber Cancer Institute;   Stand Up To Cancer
  Recruiting
• Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

  NCT03922451

  Condition:   Drug Effect
  Interventions:   Drug: piperacillin-tazobactam;   Drug: Cefazolin
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy

  NCT03857074

  Conditions:   Epilepsy;   Epilepsy Intractable
  Intervention:   Device: Green Light Exposure
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence

  NCT03786224

  Conditions:   Cannabis Use;   Adolescent Behavior
  Intervention:   Behavioral: Contingency Management
  Sponsor:   Massachusetts General Hospital
  Recruiting
• A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors

  NCT03768336

  Condition:   Cancer
  Interventions:   Other: Waitlist control;   Other: 3RP-AYA
  Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
  Recruiting
• The Role of Estrogen in the Neurobiology of Eating Disorders

  NCT03740204

  Conditions:   Eating Disorders;   Hypoestrogenemia
  Interventions:   Drug: 17-β estradiol transdermal patches with cyclic progesterone;   Drug: Placebo patch and pill
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer

  NCT03709225

  Conditions:   Anxiety;   Oncology;   Stress
  Intervention:   Behavioral: Music-based meditation
  Sponsor:   Dana-Farber Cancer Institute
  Recruiting
• Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

  NCT03553875

  Conditions:   Autism;   Autism Spectrum Disorder;   Nonverbal Learning Disability
  Interventions:   Drug: Memantine Hydrochloride;   Drug: Placebo
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease

  NCT03462979

  Conditions:   Celiac Disease;   Gluten Sensitivity;   Gluten Enteropathy;   Gastrointestinal Disease;   Digestive System Disease;   Diet Modification;   Intestinal Disease;   Malabsorption Syndromes;   Patient Compliance;   Diagnostic Self Evaluation;   Quality of Life
  Intervention:   Device: Immunochromatographic lateral flow test
  Sponsors:   Boston Children’s Hospital;   Glutenostics, LLC
  Recruiting
• Pilot Study of Metformin for Patients With Fanconi Anemia

  NCT03398824

  Condition:   Fanconi Anemia
  Intervention:   Drug: metformin HCl
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation

  NCT03281889

  Condition:   Brain Tumor
  Intervention:   Radiation: Proton Beam
  Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
  Recruiting
• Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness

  NCT03011151

  Conditions:   Gastroparesis;   Gastrointestinal Disorder, Functional;   Critical Illness
  Intervention:  
  Sponsor:   Boston Children’s Hospital
  Recruiting
• The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy

  NCT02952222

  Condition:   Anesthesia
  Interventions:   Drug: Dexmedetomidine;   Drug: Propofol (Group P);   Drug: Propofol (Group DP)
  Sponsor:   Keira Mason
  Recruiting
• Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

  NCT02845453

  Conditions:   Substance Use Disorders;   Bipolar Disorder;   Mood Disorders
  Interventions:   Drug: Quetiapine;   Drug: Placebo
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Validation of the Hospital Asthma Severity Score (HASS)

  NCT02782065

  Condition:   Asthma
  Intervention:   Other: Not an interventional study
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

  NCT02579044

  Condition:   Progeria
  Intervention:   Drug: Everolimus and lonafarnib
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Effects of Weight Loss Surgery on Bone Health in Adolescents

  NCT02557438

  Conditions:   Obesity;   Surgery
  Interventions:   Procedure: Roux-en-Y Gastric Bypass;   Procedure: Vertical Sleeve Gastrectomy
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

  NCT04134559

  Conditions:   Hepatocellular Carcinoma, Childhood;   Hepatocellular Carcinoma;   Liver Cancer;   Liver Cancer Pediatric
  Intervention:   Drug: Pembrolizumab
  Sponsor:   Allison O'Neill
  Recruiting
• Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

  NCT03928288

  Condition:   Endometriosis
  Interventions:   Drug: Cabergoline 0.5 MG;   Drug: Placebo - Cap
  Sponsors:   Boston Children’s Hospital;   Brigham and Women's Hospital
  Recruiting
• Genomic Medicine for Ill Neonates and Infants (The GEMINI Study)

  NCT03890679

  Condition:   Pediatric: Genetic Syndrome
  Intervention:   Diagnostic Test: rapid whole genomic sequencing (rWGS)
  Sponsors:   Tufts Medical Center;   Rady Children's Hospital, San Diego;   Children's Hospital Medical Center, Cincinnati;   MOUNT SINAI HOSPITAL;   N.C. Children's Hospital;   University of Pittsburgh
  Recruiting
• Phase II Study of Proton Radiation Therapy for Neuroblastoma

  NCT02112617

  Conditions:   Neuroblastoma;   Ganglioneuroblastoma
  Intervention:   Radiation: Proton Beam Radiation Therapy
  Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
  Recruiting
• JASPER Early Intervention for Tuberous Sclerosis

  NCT03422367

  Condition:   Tuberous Sclerosis
  Intervention:   Behavioral: JASPER
  Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Boston Children’s Hospital;   Massachusetts General Hospital
  Recruiting
• High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade

  NCT03162432

  Conditions:   IBD;   Ulcerative Colitis;   Crohn Disease
  Intervention:   Drug: Vitamin D3
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Early Peanut Introduction: Translation to Clinical Practice

  NCT03019328

  Condition:   Peanut Allergy
  Intervention:   Other: Peanut in diet
  Sponsors:   Johns Hopkins University;   National Institute of Allergy and Infectious Diseases (NIAID);   Massachusetts General Hospital
  Recruiting
• Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

  NCT02355340

  Conditions:   Bone Mineral Density;   Childhood Cancer Survivors
  Interventions:   Other: Dual energy x-ray absorptiometry (DXA);   Other: Peripheral quantitative computed tomography (pQCT)
  Sponsor:   Dana-Farber Cancer Institute
  Recruiting
• Bronchopulmonary Disease (BPD) Patient Registry

  NCT00951366

  Condition:   Bronchopulmonary Disease
  Intervention:   Other: Patient Registry
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Palbociclib + Ganitumab In Ewing Sarcoma

  NCT04129151

  Conditions:   Ewing Sarcoma;   Ewing's Sarcoma Recurrent
  Interventions:   Drug: Palbociclib;   Drug: Ganitumab
  Sponsors:   Dana-Farber Cancer Institute;   1 Million 4 Anna Foundation;   Carson Sarcoma Foundation;   Teaming up to Fight Childhood Cancer;   ChemoWarrior: the eli sidler foundation;   i-ROK Foundation;   Rutledge Cancer Foundation;   Alan B. Slifka Foundation
  Recruiting
• LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

  NCT03750513

  Conditions:   Anaplastic Ependymoma;   Ependymoma
  Interventions:   Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Patient and Parent Preferences for an On-Body Automated Insulin Delivery System

  NCT03534544

  Condition:   Diabetes Mellitus, Type 1
  Intervention:  
  Sponsors:   Joslin Diabetes Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors

  NCT02153957

  Condition:   Brain Tumor
  Intervention:   Behavioral: Physical Activity
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

  NCT03996967

  Conditions:   Pneumonia, Bacterial;   Viral Infection;   Clinical Pneumonia;   Plasmodium Falciparum Malaria;   Malaria;   Infections, Respiratory
  Intervention:  
  Sponsors:   Boston University;   National Institute of Allergy and Infectious Diseases (NIAID);   Medical Research Council Unit, The Gambia, LSTMH;   Laboratory of Transnational Immunology, UMC Utrecht
  Recruiting
• Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors

  NCT03837496

  Conditions:   Breast Cancer;   Adherence, Medication
  Interventions:   Other: STRIDE;   Other: Medication Monitoring Control
  Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
  Recruiting
• Clinical Trial to Improve the Magnetic Levator Prosthesis

  NCT03818204

  Conditions:   Blepharoptosis;   Ptosis, Eyelid;   Myasthenia Gravis;   Stroke;   Traumatic Brain Injury
  Intervention:   Device: Magnetic Levator Prosthesis (MLP)
  Sponsor:   Massachusetts Eye and Ear Infirmary
  Recruiting
• Calcitriol Monotherapy for X-Linked Hypophosphatemia

  NCT03748966

  Conditions:   X-linked Hypophosphatemia;   Hypophosphatemic Rickets;   Hypophosphatemic Rickets, X-Linked Dominant
  Intervention:   Drug: Calcitriol
  Sponsors:   Massachusetts General Hospital;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Recruiting
• Pediatric Gastroparesis Registry

  NCT03680820

  Conditions:   Gastroparesis;   Gastroparesis-like Syndrome
  Intervention:  
  Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Scheduled Ketorolac Administration After Cesarean Section and Its Effect on Opioid Consumption: a Randomized Control Trial

  NCT03678675

  Conditions:   Post-operative Pain;   Post-partum Pain;   Cesarean Section Complications
  Intervention:   Drug: Ketorolac
  Sponsor:   Tufts Medical Center
  Recruiting
• Seizure Rescue Medication: Caregiver Education in a Simulation Setting

  NCT03562351

  Condition:   Status Epilepticus
  Interventions:   Other: Verbal Instructions Educational Intervention;   Other: Video Educational Intervention;   Other: Mannequin Educational Intervention
  Sponsor:   Boston Children’s Hospital
  Recruiting
• Genetics of Ehlers-Danlos Syndrome

  NCT03093493

  Conditions:   Genetics Syndrome;   Ehlers-Danlos Syndrome
  Intervention:   Diagnostic Test: Genotyping
  Sponsor:   Boston University
  Recruiting
• Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies

  NCT03059420

  Conditions:   Congenital Fibrosis of Extraocular Muscles;   Duane Retraction Syndrome;   Duane Radial Ray Syndrome;   Mobius Syndrome;   Brown Syndrome;   Marcus Gunn Syndrome;   Strabismus Congenital;   Horizontal Gaze Palsy;   Horizontal Gaze Palsy With Progressive Scoliosis;   Facial Palsy;   Facial Paresis, Hereditary, Congenital;   Third Nerve Palsy;   Fourth Nerve Palsy;   Sixth Nerve Palsy;   Synkinesis;   Ocular Motility Disorders;   Levator-Medial Rectus Synkinesis;   Athabaskan Brainstem Dysgenesis;   Tongue Paralysis;   Ninth Nerve Disorder;   Fifth Nerve Palsy;   Seventh Nerve Palsy;   Eleventh Nerve Disorder;   Twelfth Nerve Disorder;   Vagus Nerve Paralysis;   Moebius Sequence
  Intervention:  
  Sponsors:   Boston Children’s Hospital;   Howard Hughes Medical Institute;   National Eye Institute (NEI)
  Recruiting
• Low Dose Naltrexone for Chronic Pain From Arthritis

  NCT03008590

  Conditions:   Osteoarthritis;   Arthritis, Rheumatoid;   Arthritis, Psoriatic
  Interventions:   Drug: Naltrexone;   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Hereditary Risk Factors for Thyroid Cancer

  NCT02747888

  Condition:   Thyroid Cancer
  Intervention:   Genetic: •Referral to Genetic Counselor, if indicated
  Sponsor:   Dana-Farber Cancer Institute
  Recruiting
• Identification of L3-L4 Interspace in Parturients

  NCT02697747

  Condition:   Healthy
  Intervention:   Other: Education
  Sponsor:   Beth Israel Deaconess Medical Center
  Recruiting
• Novel Interventions for GWVI

  NCT02661997

  Condition:   Gulf War Veteran's Illness
  Interventions:   Behavioral: Tai Chi Intervention;   Behavioral: Wellness Intervention
  Sponsors:   VA Office of Research and Development;   Boston University;   Tufts Medical Center
  Recruiting
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

  NCT02610439

  Conditions:   Breast Carcinoma;   Neuropathy
  Intervention:   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  NCT02610426

  Condition:   Breast Carcinoma
  Intervention:   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

  NCT02610413

  Condition:   Breast Carcinoma
  Intervention:   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

  NCT02555969

  Conditions:   Amyloidosis;   Primary Amyloidosis
  Intervention:  
  Sponsor:   Tufts Medical Center
  Recruiting
• Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

  NCT00592592

  Condition:   Rhabdomyosarcoma
  Intervention:   Radiation: Proton Beam Radiation
  Sponsors:   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   Brigham and Women's Hospital;   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Recruiting
• Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

  NCT02202681

  Conditions:   Celiac Disease;   Healthy
  Intervention:   Device: OFDI Capsule
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients

  NCT02193542

  Condition:   Indication for Care or Intervention Related to Labor or Delivery With Baby Delivered
  Intervention:  
  Sponsor:   Brigham and Women's Hospital
  Recruiting
• A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

  NCT03857841

  Condition:   Bronchopulmonary Dysplasia
  Interventions:   Biological: UNEX-42;   Biological: Phosphate-buffered saline
  Sponsor:   United Therapeutics
  Recruiting
• Non-Anesthetized Plexus Technique for Infant (BPBP) MRI Evaluation

  NCT03560999

  Conditions:   Brachial Plexus Palsy Due to Birth Trauma;   Injury;   Newborn
  Intervention:  
  Sponsor:   Shriners Hospitals for Children
  Recruiting
• TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders

  NCT02836405

  Conditions:   Autism Spectrum Disorder;   Intellectual Disability
  Intervention:   Device: Transcranial Magnetic Stimulation
  Sponsors:   Boston Children’s Hospital;   Beth Israel Deaconess Medical Center;   National Institute of Mental Health (NIMH)
  Recruiting
• Identification of Genetic Causes of Bicuspid Aortic Valve Disease

  NCT01026571

  Condition:   Bicuspid Aortic Valve
  Intervention:  
  Sponsors:   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Brigham and Women's Hospital
  Recruiting
• Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders

  NCT00494169

  Conditions:   Hypogonadotropic Hypogonadism;   Kallmann Syndrome;   Puberty, Delayed;   Puberty, Precocious;   GnRH Deficiency
  Intervention:  
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

  NCT00392756

  Conditions:   Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   GnRH Deficiency
  Intervention:   Drug: gonadotropin releasing hormone (GnRH)
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Molecular and Genetic Studies of Congenital Myopathies

  NCT00272883

  Conditions:   Central Core Disease;   Centronuclear Myopathy;   Congenital Fiber Type Disproportion;   Multiminicore Disease;   Myotubular Myopathy;   Nemaline Myopathy;   Rigid Spine Muscular Dystrophy;   Undefined Congenital Myopathy
  Intervention:  
  Sponsors:   Boston Children’s Hospital;   Muscular Dystrophy Association
  Recruiting
• Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

  NCT03349242

  Condition:   Retinitis Pigmentosa
  Intervention:  
  Sponsor:   MeiraGTx UK II Ltd
  Recruiting
• Aerobic Exercise for Concussion

  NCT02959216

  Conditions:   Mild Traumatic Brain Injury;   Acute Brain Injury;   Brain Concussion
  Interventions:   Other: Aerobic Exercise;   Other: Stretching Exercise
  Sponsors:   Children's Hospital of Philadelphia;   University at Buffalo;   Boston Children’s Hospital
  Recruiting
• A Randomized Controlled Trial of Leg Length Discrepancy Techniques

  NCT02260856

  Condition:   Leg Length Discrepancy
  Interventions:   Device: Tantalum Beads & Injector;   Procedure: Percutaneous Drill Epiphysiodesis;   Procedure: Percutaneous Screw Epiphysiodesis
  Sponsors:   Hospital for Special Surgery, New York;   Boston Children’s Hospital;   The Hospital for Sick Children
  Recruiting
• Fimepinostat in Treating Brain Tumors in Children and Young Adults

  NCT03893487

  Conditions:   Diffuse Intrinsic Pontine Glioma;   Recurrent Anaplastic Astrocytoma;   Recurrent Glioblastoma;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma
  Interventions:   Drug: Fimepinostat;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   Sabine Mueller, MD, PhD;   Pacific Pediatric Neuro-Oncology Consortium;   Cannonball Kids' Cancer Foundation;   Curis, Inc.
  Recruiting
• Positive Steps to Enhance Problem Solving Skills

  NCT03092531

  Condition:   Adherence
  Intervention:   Behavioral: Positive STEPS
  Sponsor:   Brown University
  Recruiting
• PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

  NCT03139331

  Condition:   Sarcoma
  Interventions:   Drug: Pazopanib;   Drug: Irinotecan;   Drug: Temozolomide
  Sponsors:   University of California, San Francisco;   UCSF Benioff Children’s Hospital Oakland;   Dana-Farber Cancer Institute;   Alex's Lemonade Stand Foundation
  Recruiting
• Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

  NCT03728426

  Condition:   Cytomegalovirus Infections
  Intervention:   Drug: Letermovir
  Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
  Recruiting
• M6620 (VX-970) in Selected Solid Tumors

  NCT03718091

  Conditions:   Solid Tumor;   Leiomyosarcoma;   Osteosarcoma
  Intervention:   Drug: M6620
  Sponsors:   Massachusetts General Hospital;   EMD Serono
  Recruiting
• Natural History Study of Patients With Canavan Disease, CAN Inform

  NCT04126005

  Condition:   Canavan Disease
  Intervention:  
  Sponsor:   Aspa Therapeutics
  Recruiting
• Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)

  NCT03252847

  Condition:   X-Linked Retinitis Pigmentosa
  Intervention:   Genetic: AAV-RPGR
  Sponsors:   MeiraGTx UK II Ltd;   Syne Qua Non Limited;   Bionical-Emas Pharma Ltd
  Recruiting
• Non-blinded Data Collection Study of Concussion Using the BrainPulse(TM)

  NCT02812225

  Conditions:   Brain Concussion;   Mild Traumatic Brain Injury
  Intervention:   Device: BrainPulse
  Sponsor:   Jan Medical, Inc.
  Recruiting
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

  NCT01804166

  Condition:   Hepatosplenic T-Cell Lymphoma
  Interventions:   Drug: Infliximab;   Drug: Golimumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

  NCT03654716

  Conditions:   Leukemia;   Brain Tumor;   Solid Tumor;   Lymphoma
  Interventions:   Drug: ALRN-6924;   Drug: Cytarabine
  Sponsors:   Dana-Farber Cancer Institute;   TeamConnor Childhood Cancer Foundation;   Cookies for Kids' Cancer;   Aileron Therapeutics
  Recruiting
• Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial

  NCT03045276

  Conditions:   Spina Bifida;   Kidney Transplant
  Interventions:   Behavioral: Behavioral Feedback and Economic Incentives: Arm 1;   Behavioral: Behavioral Feedback and Economic Incentives: Arm 2
  Sponsors:   Children's Hospital of Philadelphia;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Boston Children’s Hospital;   Children's Healthcare of Atlanta;   Children's Mercy Hospital Kansas City;   Ann & Robert H Lurie Children's Hospital of Chicago;   Seattle Children's Hospital
  Recruiting
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

  NCT02909777

  Conditions:   Lymphoma;   Neuroblastoma;   Brain Tumor;   Solid Tumor
  Intervention:   Drug: CUDC-907
  Sponsors:   Dana-Farber Cancer Institute;   Curis, Inc.
  Recruiting
• Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

  NCT04181723

  Condition:   Rett Syndrome
  Interventions:   Drug: Trofinetide;   Other: Placebo
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)

  NCT03910075

  Conditions:   Perinatal Stroke;   Hemiparesis
  Interventions:   Behavioral: I-ACQUIRE - High Dosage;   Behavioral: I-ACQUIRE - Moderate Dosage;   Behavioral: Usual & Customary Treatment (U&CT)
  Sponsors:   Virginia Polytechnic Institute and State University;   Ohio State University;   Nationwide Children's Hospital;   Stanford University;   University of Cincinnati;   Medical University of South Carolina
  Recruiting
• iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

  NCT03815019

  Conditions:   Feeding Behavior;   Feeding Disorder of Infancy or Early Childhood
  Interventions:   Drug: Megestrol Acetate;   Behavioral: iKanEat Behavioral Intervention
  Sponsor:   University of Kansas Medical Center
  Recruiting
• Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

  NCT03831880

  Condition:   Growth Hormone Deficiency
  Interventions:   Drug: Genotropin;   Drug: somatrogon
  Sponsor:   Pfizer
  Recruiting
• Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

  NCT01858168

  Conditions:   Ewing Sarcoma;   Rhabdomyosarcoma
  Interventions:   Drug: Olaparib;   Drug: Temozolomide;   Drug: Irinotecan
  Sponsor:   Massachusetts General Hospital
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Single Ascending Dose Study in Participants With LCA10

  NCT03872479

  Conditions:   Blindness;   Leber Congenital Amaurosis 10;   Vision Disorders;   Eye Diseases;   Eye Diseases, Hereditary;   Eye Disorders Congenital;   Retinal Disease;   Retinal Degeneration
  Intervention:   Drug: AGN-151587
  Sponsors:   Allergan;   Editas Medicine, Inc.
  Recruiting
• Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

  NCT03364231

  Condition:   Waldenstrom Macroglobulinemia
  Intervention:   Drug: Umbralisib
  Sponsor:   TG Therapeutics, Inc.
  Recruiting
• Low-Dose Atropine for Treatment of Myopia

  NCT03334253

  Condition:   Myopia
  Interventions:   Drug: Atropine;   Other: Placebo Eyedrops
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Recruiting
• Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

  NCT02437851

  Conditions:   Anal Squamous Cell Carcinoma;   HIV Infection;   Stage 0 Anal Canal Cancer;   Stage I Anal Canal Cancer
  Intervention:   Procedure: Therapeutic Conventional Surgery
  Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   AIDS and Cancer Specimen Resource;   University of Arkansas
  Recruiting
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT03138655

  Conditions:   Ulcerative Colitis;   Crohn's Disease
  Intervention:   Drug: Vedolizumab
  Sponsor:   Takeda
  Recruiting
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials

  NCT03531814

  Conditions:   Neurofibromatosis 1;   Neurofibroma, Plexiform
  Intervention:   Behavioral: Medication Event Monitoring System (MEMS)
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• OT-58 as an Enzyme Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

  NCT03406611

  Condition:   Homocystinuria
  Interventions:   Drug: OT-58;   Drug: Placebo
  Sponsor:   Orphan Technologies Ltd
  Recruiting
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

  NCT01302847

  Condition:   HIV Infections
  Interventions:   Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• TechStep: Technology-based Stepped Care to Stem Transgender Adolescent Risk Transmission

  NCT04000724

  Condition:   HIV
  Interventions:   Behavioral: Text Messaging (Text+Step);   Behavioral: WebApp (App+Step);   Behavioral: Information/No Step
  Sponsors:   Friends Research Institute, Inc.;   San Diego State University;   University of North Carolina;   Emory University;   Texas Children's Hospital;   Children's Hospital of Philadelphia;   The Fenway Institute;   Hunter College of City University of New York;   Children's Hospital Los Angeles
  Recruiting
• A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

  NCT03633058

  Condition:   Rett Syndrome
  Intervention:   Drug: Ketamine
  Sponsors:   Rett Syndrome Research Trust;   Vanderbilt University Medical Center
  Recruiting
• Kids FACE FEARS Comparative Effectiveness Research

  NCT03707158

  Conditions:   Child Anxiety;   Anxiety Disorder of Adolescence
  Interventions:   Behavioral: Office-based Cognitive-Behavioral Therapy;   Behavioral: Digital Cognitive-Behavioral Therapy
  Sponsors:   Boston Medical Center;   Patient-Centered Outcomes Research Institute;   Massachusetts General Hospital;   South Boston Community Health Center;   Johns Hopkins University;   Dundalk Pediatric Associates;   Harborview Injury Prevention and Research Center;   Seattle Children's Hospital;   Swedish Medical Center;   Nicklaus Children's Hospital f/k/a Miami Children's Hospital;   Boston University;   Florida International University;   University of Washington
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

  NCT03126916

  Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Drug: Melphalan;   Drug: Melphalan Hydrochloride;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• STRIDE Biorepository

  NCT02843347

  Condition:   Anemia, Sickle Cell
  Intervention:   Procedure: Blood draw
  Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

  NCT02766465

  Condition:   Sickle Cell Disease
  Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Hematopoietic Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
  Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program;   Emory University
  Recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Participants With 15Q Duplication Syndrome or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

  NCT03694275

  Conditions:   15q Duplication Syndrome;   CDKL5 Deficiency Disease
  Intervention:   Drug: TAK-935
  Sponsors:   Takeda;   Ovid Therapeutics Inc.
  Recruiting
• A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

  NCT03914625

  Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
  Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292

  Conditions:   Anaplastic Astrocytoma;   Glioblastoma;   Malignant Glioma
  Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)

  NCT03245840

  Condition:   Eosinophilic Esophagitis (EoE)
  Intervention:   Drug: Budesonide oral suspension
  Sponsor:   Shire
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

  NCT03057626

  Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

  NCT02772965

  Condition:   Pediatric Crohn's Disease
  Interventions:   Drug: Methotrexate;   Other: Sugar pill (placebo)
  Sponsors:   University of North Carolina, Chapel Hill;   Patient-Centered Outcomes Research Institute;   ImproveCareNow (ICN);   The Leona M. and Harry B. Helmsley Charitable Trust;   Children's Hospital Medical Center, Cincinnati;   Grifols Diagnostics Solutions, Inc;   National Institutes of Health (NIH);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Recruiting
• A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

  NCT02601937

  Conditions:   Rhabdoid Tumors;   INI1-negative Tumors;   Synovial Sarcoma;   Malignant Rhabdoid Tumor of Ovary
  Intervention:   Drug: Tazemetostat
  Sponsor:   Epizyme, Inc.
  Recruiting
• LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

  NCT02205762

  Condition:   Langerhans Cell Histiocytosis
  Interventions:   Drug: Prednisone;   Drug: Vinblastine;   Drug: mercaptopurine;   Drug: INDOMETHACIN;   Drug: Methotrexate;   Drug: Cytosine Arabinoside;   Drug: 2-chlorodeoxyadenosine;   Procedure: hematopoietic stem cell transplantation (RIC-HSCT);   Biological: Intravenous immunoglobulin
  Sponsors:   North American Consortium for Histiocytosis;   Histiocyte Society
  Recruiting
• Pediatric Adenotonsillectomy Trial for Snoring

  NCT02562040

  Condition:   Sleep-Disordered Breathing
  Interventions:   Procedure: Early Adenotonsillectomy (eAT);   Behavioral: Watchful Waiting with Supportive Care (WWSC)
  Sponsors:   Brigham and Women's Hospital;   Children's Hospital of Philadelphia;   University Hospitals Cleveland Medical Center;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   University of Texas Southwestern Medical Center;   University of Rochester;   Children's Hospital of The King's Daughters;   Boston Children’s Hospital
  Recruiting
• Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

  NCT02562235

  Condition:   Hypertension, Pulmonary
  Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
  Sponsors:   Bayer;   Merck Sharp & Dohme Corp.
  Recruiting
• A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

  NCT04102189

  Conditions:   Overweight;   Obesity
  Interventions:   Drug: Semaglutide;   Drug: Placebo
  Sponsor:   Novo Nordisk A/S
  Recruiting
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

  NCT03725007

  Condition:   Juvenile Idiopathic Arthritis (JIA)
  Intervention:   Drug: Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Developing e-Health Systems to Improve Growth and Nutrition in CF

  NCT03635762

  Condition:   Cystic Fibrosis in Children
  Intervention:   Behavioral: Be In Charge
  Sponsors:   Boston Children’s Hospital;   Cystic Fibrosis Foundation;   Johns Hopkins University;   Children's Hospital Medical Center, Cincinnati
  Recruiting
• Flourish™ Pediatric Esophageal Atresia

  NCT03615495

  Conditions:   Esophageal Atresia;   Digestive System Abnormalities;   Esophageal Disorders Congenital
  Intervention:   Device: Flourish Pediatric Esphogeal Atresia device
  Sponsor:   Cook Research Incorporated
  Recruiting
• Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

  NCT00550992

  Condition:   Leukemia
  Interventions:   Biological: anti-thymocyte globulin;   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: prednisolone;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation
  Sponsors:   Dutch Childhood Oncology Group;   BFM Germany;   CORS Monza Italy;   Associazione Italiana Ematologia Oncologia Pediatrica;   Australian and New Zealand Children's Oncology Group;   BFM Austria;   CLCG France Belgium Portugal;   COALL Germany;   CPH, Czech republic;   DFCI consortium USA;   FRALLE France;   Hong Kong;   MD Anderson USA;   NOPHO Scandinavian countries;   PINDA, Chile;   PPLLSG Poland;   Seattle USA;   SJCRH USA;   UKCCSG United Kingdom
  Recruiting
• CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

  NCT03924219

  Conditions:   Heart Transplant Infection;   Kidney Transplant Infection;   Liver Transplant Infection;   CMV
  Intervention:   Other: CMV T cell Immunity Assay
  Sponsors:   Vanderbilt University Medical Center;   ViraCor Laboratories
  Recruiting
• A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

  NCT03875534

  Condition:   Achondroplasia
  Intervention:  
  Sponsor:   Ascendis Pharma A/S
  Recruiting
• A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

  NCT03755713

  Condition:   Peanut Allergy
  Interventions:   Drug: ASP0892;   Drug: Placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Safety and PK Study of IV Eravacycline

  NCT03696550

  Condition:   Bacterial Infections
  Intervention:   Drug: Eravacycline (TP-434)
  Sponsor:   Tetraphase Pharmaceuticals, Inc.
  Recruiting
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

  NCT03691779

  Condition:   Cystic Fibrosis
  Interventions:   Drug: VX-445;   Drug: TEZ;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Recruiting
• Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

  NCT02204904

  Conditions:   X-Linked Adrenoleukodystrophy (X-ALD);   Cerebral Adrenoleukodystrophy (CALD);   Adrenoleukodystrophy (ALD)
  Intervention:   Genetic: Allo-HSCT
  Sponsor:   bluebird bio
  Recruiting
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

  NCT03332095

  Condition:   HIV Infections
  Interventions:   Drug: Doravirine (DOR);   Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF);   Drug: Antiretroviral (ARV) medications
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

  NCT03292588

  Condition:   Asthma
  Interventions:   Biological: Mepolizumab;   Drug: Placebo
  Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium;   GlaxoSmithKline
  Recruiting
• Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

  NCT03113760

  Conditions:   NLRC4-MAS;   XIAP Deficiency
  Interventions:   Drug: Tadekinig alfa;   Other: 0.9% sodium chloride
  Sponsor:   AB2 Bio Ltd.
  Recruiting
• AVATAR Anesthesia Alternative in Pediatric Radiotherapy: A Multi-Center Study

  NCT03991156

  Condition:   Anesthesia
  Interventions:   Device: Audio-Visual Assisted Therapeutic Ambience in Radiotherapy;   Other: Quality of Life Survey, PedsQL3.0;   Other: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)
  Sponsor:   Stanford University
  Recruiting
• Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

  NCT03940586

  Condition:   Cytomegalovirus (CMV) Infection
  Interventions:   Drug: Letermovir oral granules;   Drug: Letermovir tablet;   Drug: Letermovir intravenous
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Pediatric ACL: Understanding Treatment Options

  NCT02772770

  Condition:   Anterior Cruciate Ligament Reconstruction
  Interventions:   Other: Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions;   Procedure: Surgical technique: Transphyseal reconstruction;   Procedure: Surgical technique: Partial transphyseal reconstruction;   Procedure: Surgical technique: Physeal sparing reconstruction by the Anderson method;   Procedure: Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method
  Sponsors:   Boston Children’s Hospital;   Children's Hospital of Philadelphia;   Children's Hospital Medical Center, Cincinnati;   Rady Children's Hospital, San Diego;   Washington University School of Medicine;   Children's Healthcare of Atlanta;   The Cleveland Clinic;   Tennessee Orthopedic Alliance;   Hospital for Special Surgery, New York;   Stanford University
  Recruiting
• Cockroach Immunotherapy in Children and Adolescents

  NCT03541187

  Condition:   Persistent Asthma
  Interventions:   Biological: German cockroach allergenic extract;   Biological: Placebo for German cockroach allergenic extract
  Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Inner-City Asthma Consortium
  Recruiting
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668

  Conditions:   Melanoma;   Lymphoma;   Solid Tumor;   Classical Hodgkin Lymphoma;   Microsatellite-instability-high Solid Tumor
  Intervention:   Biological: Pembrolizumab
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

  NCT03217136

  Condition:   Complicated Intra-Abdominal Infection
  Interventions:   Drug: Ceftolozane;   Drug: Tazobactam;   Drug: Metronidazole;   Drug: Meropenem;   Drug: Placebo for Metronidazole
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

  NCT02124772

  Condition:   Cancer
  Interventions:   Drug: Trametinib;   Drug: Dabrafenib
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Dyslipidemia of Obesity Intervention in Teens

  NCT02956590

  Conditions:   Dyslipidemia;   Obesity
  Interventions:   Drug: Pitavastatin;   Drug: Placebo
  Sponsors:   New England Research Institutes;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

  NCT04110145

  Condition:   Functional Constipation
  Interventions:   Drug: Linaclotide;   Drug: Placebo
  Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc.
  Recruiting
• Linaclotide Safety and Efficacy, Functional Constipation, in Pediatric Participants 6 to 17 Years of Age

  NCT04026113

  Condition:   Functional Constipation
  Interventions:   Drug: Linaclotide 72 μg;   Drug: Placebo
  Sponsors:   Allergan;   Ironwood Pharmaceuticals, Inc.
  Recruiting
• Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

  NCT04007991

  Condition:   Tourette Syndrome in Children; Tourette Syndrome in Adolescents
  Intervention:   Drug: Ecopipam
  Sponsor:   Emalex Biosciences Inc.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

  NCT03979313

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Placebo
  Sponsor:   MedImmune LLC
  Recruiting
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

  NCT03959488

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Palivizumab
  Sponsor:   MedImmune LLC
  Recruiting
• The Safety and Efficacy of SYD-101 in Children With Myopia

  NCT03918915

  Conditions:   Nearsightedness;   Near Sightedness;   Near-sightedness
  Interventions:   Drug: SYD-101 Dose 1;   Drug: SYD-101 Dose 2;   Drug: Vehicle
  Sponsor:   Sydnexis, Inc.
  Recruiting
• Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

  NCT03916185

  Condition:   Respiratory Syncytial Virus (RSV)
  Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L Vaccine;   Biological: RSV 6120/ΔNS2/1030s Vaccine;   Biological: RSV 276 Vaccine;   Biological: Placebo
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

  NCT03740919

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Drug: LY900014;   Drug: Insulin Lispro
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

  NCT03695237

  Condition:   Central Precocious Puberty (CPP)
  Intervention:   Drug: Leuprolide Acetate (LA)
  Sponsor:   AbbVie
  Recruiting
• Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

  NCT03682770

  Condition:   Peanut Allergy
  Interventions:   Drug: Dupilumab;   Drug: Placebo matching dupilumab;   Drug: AR101
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi;   Aimmune Therapeutics, Inc.
  Recruiting
• Pediatric Longitudinal Cohort Study of Chronic Pancreatitis

  NCT03672422

  Conditions:   Pancreatitis, Chronic;   Pancreatitis, Acute
  Interventions:   Diagnostic Test: Blood sample;   Behavioral: Patient questionnaires;   Diagnostic Test: Saliva sample;   Diagnostic Test: Urine sample
  Sponsors:   Aliye Uc;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

  NCT03656510

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: JNJ-53718678;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

  NCT03601637

  Condition:   Cystic Fibrosis
  Interventions:   Drug: LUM;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Recruiting
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03596645

  Condition:   Colitis, Ulcerative
  Interventions:   Drug: Golimumab;   Drug: Infliximab
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

  NCT03497676

  Condition:   HIV Infections
  Interventions:   Drug: Oral Cabotegravir (CAB);   Drug: Oral Rilpivirine (RPV);   Drug: Long-Acting Injectable Cabotegravir (CAB LA);   Drug: Long-Acting Injectable Rilpivirine (RPV LA);   Drug: Combination Antiretroviral Therapy (cART)
  Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   ViiV
  Recruiting
• Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

  NCT03474965

  Condition:   Sickle Cell Disease
  Intervention:   Drug: Crizanlizumab
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Developmental Impact of NICU Exposures (DINE)

  NCT03061890

  Condition:   Prematurity
  Intervention:  
  Sponsors:   Albert Einstein College of Medicine;   National Institutes of Health (NIH)
  Recruiting
• An Efficacy and Safety Study of Palovarotene for the Treatment of MO

  NCT03442985

  Condition:   Exostoses, Multiple Hereditary
  Interventions:   Drug: Palovarotene 2.5 mg;   Drug: Palovarotene 5.0 mg;   Other: Placebo
  Sponsor:   Clementia Pharmaceuticals Inc.
  Recruiting
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

  NCT03429543

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

  NCT03346434

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: Dupilumab;   Drug: Matching placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

  NCT02849457

  Condition:   Tuberous Sclerosis Complex
  Interventions:   Drug: Vigabatrin;   Drug: Placebo
  Sponsors:   Martina Bebin;   National Institute of Neurological Disorders and Stroke (NINDS)
  Recruiting
• Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

  NCT03227029

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L;   Biological: RSV 276;   Biological: Placebo
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission

  NCT03223753

  Condition:   Acute Lymphoblastic Leukemia in Remission
  Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

  NCT03211247

  Condition:   Peanut Allergy
  Interventions:   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Placebo
  Sponsor:   DBV Technologies
  Recruiting
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT03196427

  Conditions:   Ulcerative Colitis;   Crohn's Disease
  Intervention:   Drug: Vedolizumab
  Sponsor:   Takeda
  Recruiting
• Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

  NCT03182907

  Condition:   Clostridium Difficile Infection
  Interventions:   Biological: Bezlotoxumab;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

  NCT03170518

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

  NCT03107871

  Conditions:   Cmv Congenital;   CMV;   Congenital Cmv;   SNHL;   Sensorineural Hearing Loss
  Interventions:   Drug: Valganciclovir;   Drug: Simple Syrup
  Sponsors:   Albert Park;   National Institute on Deafness and Other Communication Disorders (NIDCD);   Genentech, Inc.
  Recruiting